Loading...
•
Jun 30, 2021
Bioxcel Therapeutics Q2 2021 Earnings Report
BioXcel Therapeutics reported financial results for the second quarter ended June 30, 2021 and provided an update on key strategic initiatives.
Key Takeaways
BioXcel Therapeutics reported a net loss of $27.6 million for the second quarter of 2021. As of June 30, 2021, cash and cash equivalents totaled approximately $273.1 million.
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021.
PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of agitation associated with schizophrenia and bipolar disorders I & II.
Data from adenocarcinoma cohort of Phase 1b/2 study of BXCL701 and KEYTRUDA® in aggressive forms of prostate cancer anticipated in Q3 2021.
Raised gross proceeds of approximately $100 million with a common stock offering in June to further fund ongoing clinical development studies and commercialization readiness preparations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...